References
- 1. UNAIDS. 2008 Report on the global AIDS epidemic. Geneva: WHO Library Cataloguing-in-Publication Data, 2008.
- 2. Pongpun S, Poolkasorn S, Kaesaudomthub V, Pliput T. Situation of HIV infection in Thailand 2007. Nonthaburi: Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health; 2008.
- 3. Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health of Thailand. HIV prevention and implementation in men who have sex with men. Nonthaburi: Printing House of the War Veterans Organization of Thailand; 2008.
- 4. Chasombat S, McConnell MS, Siangphoe U, Yuktanont P, Jirawattanapisal T, Fox K, et al. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr. 2009; 50:506-12.
- 5. The Thai Working Group on HIV/AIDS Projections. The Asian epidemic model (AEM) projections for HIV/AIDS in Thailand: 2005-2025. Family Health International (FHI) and Bureau of AIDS, TB and STIs, Department of Disease Control, Ministry of Public Health, Thailand. 2008.
- 6. Revenga A, Over M, Masaki E, Peerapatanapokin W, Gold J, Tangcharoensathien V, et al. The economics of effective AIDS treatment: evaluating policy options for Thailand. Washington DC: The World Bank, 2006.
- 7. Manosuthi W, Chaovavanich A, Tansuphaswadikul S, Prasithsirikul W, Inthong Y, Chottanapund S, et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resourcelimited setting. J Infect. 2007; 55:464-9.
- 8. Ormaasen V, Sandvik L, Dudman SG, Bruun JN. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population. Scand J Infect Dis. 2007; 39:51-7.
- 9. Garcia F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004; 36:702-13.
- 10. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002; 360:119-29.
- 11. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360:1815-26.
- 12. Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, et al. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3. Antivir Ther. 2007; 12:941-7.
- 13. Center for Disease Control and Prevention. Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital settings. MMWR (Mortality Morbidity Weekly Report) Recomm Rep. 1993; 42:1-6.
- 14. Center for Disease Control and Prevention. Revised recommendations for HIV screening of pregnant women. MMWR (Mortality Morbidity Weekly Report). Recomm Rep. 2001; 50:63-85.
- 15. Walensky RP, Weinstein MC, Kimmel AD, Seage Iii GR, Losina E, Sax PE, et al. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005; 118: 292-300.10.1016/j.amjmed.2004.07.055
- 16. Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006; 145:797-806.
- 17. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, 3rd, Losina E, Zhang H, et al. Expanded screening for HIV in the United States-an analysis of costeffectiveness. N Engl J Med. 2005; 352:586-95.
- 18. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005; 352:570-85.
- 19. Resch S, Altice FL, Paltiel AD. Cost-effectiveness of HIV screening for incarcerated pregnant women. J Acquir Immune Defic Syndr. 2005; 38:163-73.
- 20. Center for Disease Control and Prevention. Revised recommendations for HIV testing of adult, adolescents, and pregnant woman in health-care setting. MMWR (Mortality Morbidity Weekly Report) Recomm Rep. 2006; 55:1-17.
- 21. WHO/UNAIDS. Guidance on provider-initiated HIV testing and counselling in health facilities. Geneva:WHO press, 2007.
- 22. Teerawattananon Y, Leelukkanaveera Y, Hanvoravongchai P, Thavorncharoensap M, Ingsrisawang L, Tantivess S, et al. Provider-initiated HIV/AIDS counseling and testing at healthcare facilities in Thailand: cluster-randomisation trial. J Develop Effect. 2009; 1:450-69.
- 23. Fox-Rushby J, Cairns J. Economic Evaluation. Berkshire:Open University Press; 2008.
- 24. Fylkesnes K, Siziya S. A randomized trial on acceptability of voluntary HIV counseling and testing. Trop Med Int Health. 2004; 9:566-72.10.1111/j.1365-3156.2004.01231.x
- 25. Nuwaha F, Kabatesi D, Muganwa M, Whalen CC. Factors influencing acceptability of voluntary counselling and testing for HIV in Bushenyi district of Uganda. East Afr Med J. 2002; 79:626-32.
- 26. Thielman NM, Chu HY, Ostermann J, Itemba DK, Mgonja A, Mtweve S, et al. Cost-effectiveness of free HIV voluntary counseling and testing through a community-based AIDS service organization in Northern Tanzania. Am J Public Health. 2006; 96:114-9.
- 27. Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. Med Decis Making. 2005; 25:321-9.10.1177/0272989X05276955